Osimertinib taiwan patent expiration?

When does the osimertinib (Tagrisso) patent expire in Taiwan?

Publicly available, Taiwan-specific patent-expiration dates for osimertinib depend on the exact patent family (e.g., original drug substance vs. formulations, crystalline forms, or specific medical-use claims) and the patent numbers listed in Taiwan’s registry. The information provided here does not include those Taiwan patent identifiers or their expiry dates, so an exact expiration date cannot be confirmed from the available sources.

If you share the Taiwan patent number(s) you are looking at (or the patent holder and patent title), I can help interpret the likely expiry timeline and what to check next in Taiwan.

Does Taiwan’s patent expiry match global timelines for Tagrisso?

Not necessarily. Even when a drug’s “first approval” date is similar worldwide, Taiwan’s patent term and any adjustments/strategic filing can differ across patent jurisdictions. Also, companies often rely on multiple overlapping patents; one patent can expire while others still provide protection. Without the Taiwan patent list for the relevant osimertinib family, it’s not possible to map a single “global expiry date” onto Taiwan.

How can you verify the Taiwan expiration date yourself (practical steps)?

To pin down the exact date in Taiwan, you typically need to:
- Identify the relevant Taiwan patent(s) covering osimertinib (by patent number or assignee).
- Confirm the patent’s filing date, term, and any relevant status (e.g., active vs. expired, lapsed, or invalidated).
- Check whether the marketed product is covered by multiple patents; courts or regulators may treat protection differently depending on what claim scope is still in force.

What happens in Taiwan once protection ends?

When Taiwan’s last relevant patent in force for the drug substance and/or key claims expires (or is no longer enforceable), generic manufacturers may be able to seek approval and/or launch, subject to Taiwan’s regulatory and patent-linkage framework and any remaining barriers (such as other still-active patents).

If you want, tell me:
1) whether you mean product-launch protection (including formulation/use patents) or a specific patent family, and
2) the patent number(s) (or assignee) for osimertinib in Taiwan,
and I’ll help you derive the most likely expiration date(s) and explain what that would mean for competitors.